< Back to search
Filter
1
Featured

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Location: Columbus OH, Rochester MN, Salt Lake City UT
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05091424

Phase1, Recruiting
Active & ResponsiveNew

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Kerry Rogers

Sex: All

Age: 18+

Code: NCT07734038

Phase2, Recruiting
Active & Responsive

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT05943496

Phase1, Recruiting
Active & Responsive

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

for
Recurrent Transformed Chronic Lymphocytic Leukemia,
Location: New York NY, Columbus OH, Salt Lake City UT
Sponsor: Aseel Alsouqi

Sex: All

Age: 18+

Code: NCT05873712

Phase2, Recruiting
Active & Responsive

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

for
Chronic Lymphocytic Leukemia, B-cell Malignancies
Location: Florham Park NJ, Miami Beach FL, Pittsburgh PA,
Sponsor: Curis, Inc.

Sex: All

Age: 18+

Code: NCT07271667

Phase2, Recruiting

Interested in new leukemia, lymphocytic, chronic, b-cell trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

for
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV,
Location: Toronto, Calgary
Sponsor: AstraZeneca

Sex: All

Age: 18

Code: NCT07509151

Phase3, Recruiting
Active & Responsive

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

for
CLL / SLL, CLL (Chronic Lymphocytic Leukemia),
Location: Chapel Hill NC, Columbus OH, Cincinnati OH,
Sponsor: Lomond Therapeutics Holdings, Inc.

Sex: All

Age: 18+

Code: NCT06708897

Phase1, Recruiting
Active & Responsive

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

for
Chronic Lymphocytic Leukemia (CLL),
Location: Bethesda MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Sex: All

Age: 18 - 70+

Code: NCT07428707

Early_phase1, Recruiting
Active & Responsive

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

for
CLL/SLL
Location: Boston MA, Charlotte NC, Jacksonville FL, Canton OH,
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18 - 70+

Code: NCT04215809

Phase1, Recruiting
Active & Responsive

64Cu-LLP2A for Imaging Hematologic Malignancies

for
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06636175

Early_phase1, Recruiting
Active & Responsive

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

for
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL),
Location: Cincinnatti OH, Chicago IL, St Louis MO, Omaha NE,
Sponsor: Umoja Biopharma

Sex: All

Age: 18+

Code: NCT06528301

Phase1, Recruiting
Active & Responsive

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

for
Recurrent Acute Lymphoblastic Leukemia,
Location: Columbus OH
Sponsor: Sumithira Vasu

Sex: All

Age: 2+

Code: NCT05418088

Phase1, Recruiting
Active & Responsive

SynKIR-310 for Relapsed/Refractory B-NHL

for
B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma,
Location: New Brunswick NJ, Philadelphia PA, Atlanta GA,
Sponsor: Verismo Therapeutics

Sex: All

Age: 18+

Code: NCT06544265

Phase1, Recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT06364423

Phase1, Phase2, Recruiting

Family Study of Lymphoproliferative Disorders

for
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18 - 70+

Code: NCT00626496

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Moncton, Sherbrooke, Albany NY, Greenfield Park,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05947851

Phase3, Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

for
Hypogammaglobulinemia, Bacterial Infections,
Location: Greenville NC, Bethesda MD, Morrisville NC,
Sponsor: Grifols Therapeutics LLC

Sex: All

Age: 18+

Code: NCT05645107

Phase3, Recruiting
New

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Nashville TN, Aurora CO, Eugene OR
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07520006

Phase1, Phase2, Recruiting
New

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Fairfax VA, Macon GA, Fort Wayne IN, Indianapolis IN,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07516093

Phase3, Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for
Recurrent Chronic Lymphocytic Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04169737

Phase2, Recruiting